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Abstract
Multidrug resistance (MDR) frequently develops in cancer patients exposed to chemotherapeutic agents and is
usually brought about by over-expression of P-glycoprotein (P-gp) which acts as a drug efflux pump to reduce the
intracellular concentration of the drug(s). Thus, inhibiting P-gp expression might assist in overcoming MDR in cancer
chemotherapy. MiRNAome profiling using next-generation sequencing identified differentially expressed microRNAs
(miRs) between parental K562 cells and MDR K562 cells (K562/ADM) induced by adriamycin treatment. Two miRs,
miR-381 and miR-495, that were strongly down-regulated in K562/ADM cells, are validated to target the 3’-UTR of
the MDR1 gene. These miRs are located within a miR cluster located at chromosome region 14q32.31, and all miRs
in this cluster appear to be down-regulated in K562/ADM cells. Functional analysis indicated that restoring
expression of miR-381 or miR-495 in K562/ADM cells was correlated with reduced expression of the MDR1 gene and
its protein product, P-gp, and increased drug uptake by the cells. Thus, we have demonstrated that changing the
levels of certain miR species modulates the MDR phenotype in leukemia cells, and propose further exploration of the
use of miR-based therapies to overcome MDR.
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Introduction
Multidrug resistance (MDR) is one of the main obstacles to
the successful treatment of cancer patients with
chemotherapeutic agents. As a prevalent clinical phenotype,
cancer cells from patients who have been exposed to one
chemotherapeutic agent, become resistant to that agent and
consequently develop cross-resistance to a wide range of other
chemotherapeutic agents [1]. Efflux of hydrophobic drugs out of
cells is the most commonly encountered mechanism of MDR.
ATP-binding cassette (ABC) transporters, a superfamily of
transmembrane proteins, play pivotal roles in this process [2].
Among them, P-glycoprotein (P-gp), encoded by the MDR1
gene (also known as the ABCB1 gene), is the most well
studied [3,4].
MDR1/P-gp is expressed naturally in important physiological
barriers such as the gastrointestinal tract, liver and kidney,
where it acts as a barrier for protection against endogenous
and exogenous toxins [5]. In addition to its physiologic
expression in normal tissues, it is also expressed and, mostly,
over-expressed, in certain human tumors [6]. Tumors derived
from tissues expressing P-gp are normally resistant to
chemotherapy. In contrast, some other tumors, such as breast
tumors and leukemia, with low or no expression of P-gp,
develop MDR only after treatment with anti-cancer drugs when
the over-expression of P-gp is induced [7].
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Therapeutic use of P-gp inhibitors to overcome MDR was
first proposed in 1981 when Tsuruo et al. found that verapamil
could reverse MDR in Vincristine-resistant leukemia cells
P388/VCR [8]. To date, three generations of P-gp inhibitors
have been developed, mostly competitive or non-competitive
inhibitors targeting P-gp with increasing potency and
decreasing toxicity [9]. However, none of them have been
clinically successful because of their unwanted
pharmacokinetic interactions with chemotherapeutic agents or
because of a lack of specificity [10]. Clearly, modulation of P-gp
expression could also potentially reverse the phenotype of
MDR and it has been previously shown that P-gp activity
against certain substrates can be significantly modulated by
specific mutations. A synonymous SNP in the MDR1 gene,
C3435T, which does not cause an amino acid substitution, was
reported to be associated with low intestinal P-gp expression,
low P-gp activity, and high digoxin absorption in individuals
carrying this allele [11]. In addition, a T3587G germ-line
mutation of MDR1 expresses a non-functional P-gp [12].
However, little is known about the mechanisms regulating
expression of the MDR1 gene. A study, using the human
leukemia K562 cell line and its multidrug-resistant derivative,
K562/ADM, revealed that DNA demethylation at the repressor
binding site (the -110 GC-box) of the MDR1 gene in K562/ADM
cells is associated with up-regulation of P-gp expression [13].
Recent studies suggest that MDR1 is also regulated by
different miRs in different tumour types. For example, miR-27a
and miR-451 are activators of MDR1/P-gp expression in the
development of MDR in human ovarian and cervical cancer
cells [14] while miR-451 negatively regulates the expression of
the MDR1 gene in the multidrug-resistant breast cancer cell
line, MCF7/DOX [15]. The growing evidence of regulation of P-
gp expression by miRs led us to investigate the possibility of
using a miR-based approach to silence P-gp over-expression
in human multidrug-resistant leukemia cells.
Several technologies, such as microarrays and PCR-based
arrays, have been developed for genome-wide miR expression
profiling [16]. However, massively parallel sequencing, which
not only provides accurate measurements of miR profiles but
also enables the identification of novel miRs and other small
RNAs, has not been widely utilized in miR screening. Taking
advantage of this technology, we investigated the differentially-
expressed miRs in the K562 human leukemia cell line, (derived
from a chronic myelogenous leukemia patient) and multidrug-
resistant K562/ADM cells, and identified and validated key miR
candidates whose expression is inversely related to that of P-
gp. We also present evidence that modulation of miR
expression reduces the effects of the MDR phenotype with
drug uptake being increased in MDR leukemia cells treated
with adriamycin or vinblastine.
Materials and Methods
Cell culture and generation of MDR cell lines
Human chronic myelogenous leukemia K562 cells bought
from ECACC (Sigma) were cultured in complete RPMI 1640
medium with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin at 37°C in a humidified atmosphere containing
5% CO2.
A stable adriamycin (ADM, Sigma)-resistant cell line variant
(K562/ADM) was established from K562 by continuous
exposure of the cells to increasing concentrations of ADM up to
1000 ng/mL. Subsequently, K562/ADM cells were cultured in
the presence of 1000 ng/mL of ADM to maintain the drug-
resistant phenotype. Similarly, another multidrug-resistant cell
line, K562/VBL, was established from K562 by continuous
exposure of the cells to an increasing concentration of
vinblastin (VBL, Sigma) up to 500 ng/mL.
HCA2-hTERT cells were cultured in MEM media with 15%
fetal bovine serum, 100 units/mL penicillin and 100μg/mL
streptomycin at 37°C.
cDNA synthesis and real time-PCR
Total RNA was prepared from cells using TriReagent
(Sigma-Aldrich) according to the manufacturer’s instructions.
RNA (1µg) was treated with DNase I (1U) in Tris buffer (pH 7.6)
containing 5 mM MgCl2 at 37°C for 30 min, and reverse-
transcribed using first-strand cDNA Synthesis (Marligen, USA)
as detailed in the manufacturer’s instructions. Real-time PCR
reactions were performed with 50 ng of cDNA and Power
SYBR® Green PCR Master Mix (ABI) in a total volume of 20 µL
on an ABI 7500 sequence detector (Applied Biosystems).
Details of the primers used for the measurement of gene
expression are listed in Table S1. The Ct values for the genes
of interest were normalized to that of Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) whose expression did not
change in response to the drug treatment.
Surface staining and FACS analysis
To analyze the expression of P-gp, K562, K562/ADM and
K562/VBL cells (approximately 1×106 cells) were stained with
20 µL monoclonal anti-human P-gp 17F9 antibody labeled with
PE (BD Biosciences) for 30 min at 4°C in the dark. The binding
affinity of the P-gp antibody was measured by a FACSCalibur
flow cytometer (Becton Dickinson, USA). The data were
analyzed using FlowJo software.
MTT assay
Increasing concentrations of VBL dissolved in 50 μL
RPMI-1640 were added to cell suspensions (1×105/mL, 200
μL) in 96-well culture plates and incubated for 48 h. RPMI-1640
(50 μL) without VBL was added to the cells as a negative
control and RPMI-1640 (250 μL) without cells was used as a
blank control. MTT (20 μL of 5 mg/mL) was added and
incubated for an additional 4 h.
FACS analysis of Rhodamine 123 accumulation
Rhodamine 123 (Rh123, Sigma) is a fluorescent substrate of
P-gp that has been extensively used as an index of P-gp-
mediated transport in MDR cells[17]. Both K562 and
K562/ADM cells were collected and incubated with 5 µM
Rh123 at 37°C for 30 min. Cells were washed 3 times and
resuspended in chilled PBS prior to measurement of
intracellular Rh123 content with a FACSCalibur flow cytometer.
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Next-generation sequencing and bioinformatic analysis
of the miRNAome
Total RNA was isolated from K562 and K562/ADM cells and
enriched using PEG to precipitate HMW RNAs[18]. Small RNA
libraries for sequencing were prepared based on Illumina’s
alternative v1.5 protocol and a published method [18], and
sequenced on an Illumina Genome Analyzer IIx at the ACRF
Biomolecular Resource Facility of the Australian National
University.
Mapping of Illumina short-read data was carried out with the
miRanalyzer web server [19]. For both the K562 and
K562/ADM small RNA-Seq datasets, files containing the 36-
mer reads in fastq format were first processed using a Perl
script (groupGAreads.pl) downloaded from the miRanalyzer
website. This script condenses each fastq file into a smaller file
containing each unique read and the number of times it occurs
and greatly reduces the size of the files to be uploaded.
Singleton reads were omitted from further analysis. The
condensed read files were uploaded to the miRanalyzer web
server where the Illumina adapter sequence was identified and
removed from each read before mapping with the Bowtie
alignment program against the “miRBase 16” database and
other libraries of transcribed sequences. Default parameters for
miRanalyzer were used throughout. Following mapping,
normalization of the reads and analysis of differential
expression was carried out with the R/Bioconductor DESeq
package built-in to miRanalyzer[20].
Validation of miRs
Expression profiling of mature miRs was determined using
stem-loop real-time PCR with minor modifications [21,22].
Specific stem-loop real-time primers uniquely recognizing each
miR were designed according to Chen et al. [22] (Table S2).
Following initial denaturing, annealing and reverse transcription
using Superscript III reverse transcriptase (Invitrogen),
products underwent real-time PCR using Power SYBR® Green
PCR Master Mix. Their Ct values were normalized to that of
miR-425 whose expression did not change in response to the
drug treatment.
EGFP Reporter Assay for targeting the 3'-UTR of MDR1
The 3’-untranslated region (UTR) segment of the MDR1
gene corresponding to a region of 611 bp (nucleotide positions
4,262-4,872 of the total transcript) (accession no.
NM_000927.3) was amplified by PCR from human cDNA using
primers with Not I tails on both forward and reverse strands.
PCR products were digested with Not I restriction
endonuclease and then ligated into a pEGFP-N1 vector
(Clontech) at the Not I site located upstream of the
polyadenylation signals of enhanced green fluorescent protein
(EGFP). The EGFP-MDR1 3’-UTR reporter vector construct
(25 ng) was co-transfected with 100 nM of the miR-381 or
miR-495 mimics or negative control miRs into HCA2-hTERT
cells using a Nucleofector 4D (Lonza). pDsRed2-N1 vector (5
ng) was co-transfected as an internal control. Two days after
transfection, cells were collected and analysed on a
FACSCalibur flow cytometer [23].
MiR Transfection
Custom designed miR mimics for miR-381, miR-495 and a
negative control with a scrambled sequence were synthesized
by Sigma (Table S3). Cell transfections were performed with
Nucleofector kits on a Nucleofector I or Nucleofector 4D.
Transfections were optimized according to the manufacturer’s
protocol. Briefly, 1×106 cells were resuspended in Nucleofector
solution containing 100 nM of miR-381, miR-495, mimics or
scrambled sequences as a negative control miR. The cell
mixtures were transfected in Nucleovettes in the Nucleofector
machine with the appropriate program. Similarly, miRCURY
LNATM miR inhibitors (EXIQON) (Table S4) for miR-381,
miR-495 and the scrambled sequence negative control were
delivered into K562/ADM cells that had been pre-transfected
with mimics.
Microscopy images of intracellular Rh123
MiR-transfected cells were incubated with 5 µM Rh123 at
37°C for 30 min [24]. Cells were washed 3 times with ice cold
PBS before microscopic images were collected with an
Olympus IX71 inverted microscope (Melville, NY) with DP
Controller and DP Manager Software.
Statistical analysis
The results are expressed as mean ± standard deviation
(SD) of at least three independent experiments. The statistical
significance was calculated with a student’s t-test and
differences were considered statistically significant at P < 0.05.
Results
Generation of multidrug-resistant leukemia cell line
To analyze the changes in miR profiles during the
development of MDR in leukemia cells, we first generated a
MDR cell line from drug-sensitive K562 cells. K562 cells were
treated with ADM for a prolonged period of time (approximately
5 months), leading to morphological changes and the
development of a stable cell line referred to as K562/ADM
(Figure S1A). To confirm that K562/ADM had acquired the
MDR phenotype, we first examined the expression of P-gp at
both the mRNA and protein levels. An approximate 5000-fold
increase in MDR1 mRNA expression was stably achieved in
K562/ADM cells compared to the parental K562 cells after
prolonged induction with ADM (Figure 1A). The levels of P-gp
in both K562 and K562/ADM cells were determined by cell
surface staining with an anti-P-gp antibody followed by FACS
analysis (Figure 1B). In contrast to the parental K562 cells with
low P-gp expression, a single population of K562/ADM cells
with elevated P-gp expression was produced. The substrate
efflux function of P-gp was verified by measuring the cell
survival rate during exposure to the anticancer drug VBL in
MTT assays, and by measuring the accumulation of Rh123 in
cells by FACS analysis (Figure 1C and 1D). Both VBL and
Rh123 are substrates of P-gp. MTT assays revealed that a
higher concentration of VBL was needed to inhibit cell growth
in K562/ADM cells than in K562 cells and Rh123 accumulation
assays indicated that far less substrate accumulated in
miR-381 and miR-495 Modulate MDR1 Gene Expression
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K562/ADM cells probably due to P-gp over-expression in this
cell line compared to the parental cells, suggesting that
K562/ADM is an MDR cell line.
Another MDR cell line (K562/VBL) induced by VBL exposure
developed a phenotype similar to K562/ADM with elevated
expression of MDR1/P-gp (Figure S1).
Genome-wide miR expression profiling in K562 and
K562/ADM cells
Small RNA libraries were prepared from the K562 and
K562/ADM cells as described in Materials and Methods and
sequenced on an Illumina Genome Analyzer IIx. Mapping of
the Illumina reads was carried out on the miRanalyzer web
server [19]. For both the K562 and K562/ADM samples, about
30 million raw reads were obtained, from which 905,747 and
644,790 non-singleton unique reads respectively, were
extracted along with their copy numbers. A brief summary of
the reads mapping to known mature miR sequences and other
transcribed libraries is presented in Table 1. After mapping and
aligning these candidates to the 1032 recorded sequences of
mature miRs in “miRBase 16”, 564 and 587 mature miRs were
found to be expressed in K562 and K562/ADM cells,
respectively.
The raw counts of reads mapping to known miRs were then
input to the DESeq package as implemented in miRanalyzer
for normalization of the two libraries and calculation of fold
Figure 1.  Generation of K562/ADM cells.  (A) K562/ADM cells were established after exposure of K562 cells to ADM. MDR1
expression in parental and drug-treated K562 cells was normalized to the GAPDH housekeeping gene. (B) FACS analysis of K562
and K562/ADM cells stained with P-gp antibody. (C) MTT assay shows survival rate of K562 and K562/ADM cells under VBL
treatment. The ratio of OD490 of VBL-treated cells versus control cells was used as the measure of survival rate. At least three
independent experiments were performed and error bars represent standard deviation (S.D.). (D) FACS analysis of Rh123
accumulation in K562 and K562/ADM cells.
doi: 10.1371/journal.pone.0082062.g001
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changes of miRs between the two samples. This revealed
numerous large differences in the miR profiles of the two cell
types. Of the differentially expressed miRs with raw p-values
for differential expression less than 0.01, most were down-
regulated in K562/ADM cells. The differentially expressed miRs
with fold changes greater than 2 were selected and mapped to
the UCSC human genome assembly (GRCh37/hg19, February
Table 1. Mapping results for small RNA-Seq data.
Mapping results Samples
 K562 K562/ADM
Total number of reads 27,387,744 31,350,659
Total number of unique reads excluding singleton reads 905,747 644,790
Unique reads mapped to other transcribed libraries
(RefSeq_genes and Rfam) 74,495 72,903
Unique reads of mature miRs 32,822 33,120
Number of known mature miRs recorded in miRBase16 1,032 1,032
Number of different types of mature miRs detected in
sample 564 587
doi: 10.1371/journal.pone.0082062.t001
2009) using the BWA short read aligner. Figure 2 represents
the fold changes of these selected miRs in MDR cells mapped
across all of the human chromosomes. Notably, a large
proportion of miRs that were down-regulated in MDR cells
mapped to locations on chromosome 14.
Figure 2 also presents an overview of the chromosomal
distribution of up-regulated miRs with fold change > 2. In
addition, up-regulated miRs with fold-changes > 10 are listed in
Table S5. Interestingly, there are not many miRs displaying
>10-fold increase in expression in K562/ADM cells. This leads
us to a further speculation that the dysregulated miRs are
those that are down-regulated in MDR cells.
Identification and validation of candidate miRs
Using the microRNA.org and TargetScan databases,
approximately 14 of the down-regulated miRs are predicted to
target the 3’-UTR of the MDR1 gene (Figure 3A and 3B). Three
of them, miR-381, miR-485-3p and miR-495, were down-
regulated approximately 100-fold in K562/ADM cells compared
to K562 cells (Figure 2 and Table 2). However, miR-485-3p is
poorly conserved in the sequence region that putatively binds
to the MDR1 3'-UTR according to TargetscanHuman 6.2. Thus,
Figure 2.  Manhattan plot of the chromosomal distribution of differentially expressed miRs.  The x-axis represents the 23
human chromosomes end-to-end; the y axis shows the expression changes of individual miRs in K562/ADM cells based on miR-seq
profiling. Only differentially-regulated miRs showing 2-fold or greater changes in their expression are shown. Grey dots represent
miRs on chromosomes 1, 3, 5, 7, and 9 etc. while black dots are miRs on even numbered chromosomes. No miR with a 2-fold or
greater fold change mapped to chromosome 21.
doi: 10.1371/journal.pone.0082062.g002
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the other two miRs, miR-381 and miR-495, were selected as
candidates for further study.
The expression of miR-381 and miR-495 was validated by
the stem-loop real-time PCR method. MiR-16 was selected as
a negative control and miR-425 as an internal control for Ct
value calculations because miR-425 showed very little
difference between K562 and K562/ADM cells from the
genome-wide expression profiling data. Compared to parental
K562 cells, there was an approximately 100-fold decrease in
expression, by stem-loop real-time PCR, of miR-381 and
miR-495 in K562/ADM cells (Figure 3C), supporting the results
from the genome-wide study (Figure 2 and Table 2).
Figure 3.  Validation of mature miR expression.  (A) Schematic representation of miRs targeted to the 3'-UTR of the MDR1
mRNA predicted by microRNA.org. MiR-381 and miR-495 are highlighted and their predicted seed binding regions are shown in (B).
Numbers at both ends of the fragments represent the relative nucleotide locations in this region. (C) Expression of mature miR-381,
miR-495 and miR-16 in K562 and K562/ADM cells was validated by stem-loop real-time PCR. The Ct values of these miRs were
normalized to that of miR-425 whose expression was unchanged in both cell types. Next, the relative expression of miR-381,
miR-495 and miR-16 in K562 cells and in K562/ADM cells was calculated. The results are shown as the mean ± SD of three
independent experiments. (D) The Ct values of miR-381, miR-495 and miR-16 in K562 and K562/VBL cells were normalized to
miR-425. The relative expression of miR-381, miR-495 and miR-16 in K562 cells and in K562/VBL cells was calculated. The results
are shown as the mean ± SD of three independent experiments.
doi: 10.1371/journal.pone.0082062.g003
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Similar down-regulation of miR-381 and miR-495 was also
observed in the other MDR cell line, K562/VBL, which also
expressed MDR1/P-gp at high levels similar to K562/ADM
(Figure 3D; Figure S1), suggesting a common phenomenon in
MDR leukemia cells in which MDR1 gene expression is
negatively correlated with miR-381 and/or miR-495 expression
levels.
MiR-381 and miR-495 expression is negatively
correlated with MDR1/ P-gp expression and function
The functional importance of miR-381 and miR-495 in
relation to MDR1/P-gp expression was evaluated by
manipulating their levels using mimics and inhibitors of these
miRs, with scrambled sequences as negative controls. As
shown in Figure 4A, K562/ADM cells transfected with miR-381
and miR-495 mimics showed a 63% and 54% reduction in
MDR1 expression, respectively. In contrast, transfection with
each inhibitor in the mimic-treated cells led to increased MDR1
expression with no changes being observed in the negative
control. Changes in P-gp protein expression in the transfected
K562/ADM cells were confirmed by FACS analysis, and were
consistent with the changes observed in mRNA expression
(Figure 4B).
Table 2. miRs with >50-fold reduction in expression in
K562/ADM cells and their corresponding target genes
predicted by microRNA.org or TargetscanHuman 6.2.
miR-ID
Fold change of
reduction in
expression Predicted Targets
  microRNA.org TargetscanHuman 6.2
miR-381 98 MDR1,ABCC5  
miR-127-3p 51   
miR-411 68 ABCG2,  
miR-379 67 ABCC1,ABCC2 ABCC2
miR-299-3p 104   
miR-494 322 SRI,GLO-1 GLO-1,ABCC5
miR-376c 65 SRI ABCC4
miR-376a 130   
miR-369-3p 131  GLO-1,ABCC5
miR-380 103  GLO-1
miR-409-3p 116   
miR-485-3p 103  MDR1
miR-487b 128   
miR-495 80 MDR1,SRI,ABCC4,ABCC5 MDR1
miR-299-5p 76  ABCC1,ABCC4
miR-410 73 ABCC1,ABCC5 ABCG2
miR-376b 58   
miR-377 65   
miR-889 51  ABCC5
miR-485-5p 60  ABCC1
miR-409-5p 53  ABCG2
miR-323-3p 64  ABCG2
All the miRs listed below are located at chromosome region 14q32.31.
doi: 10.1371/journal.pone.0082062.t002
We experienced difficulties in performing experiments with
either the miR-381 or miR-495 inhibitors transfected into
parental K562 cells. No obvious change in P-gp expression
occurred when low concentrations of the inhibitor (100 nM)
were used to transfect K562 cells. However, further increases
in the concentrations of the inhibitors caused serious toxicity
eventually leading to cell death (data not shown).
To further confirm the potential role of miR-381 or miR-495 in
regulating P-gp expression, we assessed the membrane
transporter activity of P-gp by observing intracellular Rh123
content using fluorescence inverted microscopy (Figure 4C).
Rh123 accumulation was increased in K562/ADM cells treated
with mimics of miR-381 or miR-495, but this accumulation was
counteracted upon transfection with the inhibitors, indicating
that the miRs could reverse the MDR1/P-gp expression and
thus restore substrate accumulation.
Cytotoxicity of K562/ADM cells under treatment with
Vincristine (VCR) was analyzed by counting the number of live
cells using Muse™ Count and Viability kits. As shown in Figure
4D, in comparison to the negative control group, miR-495 or
miR-381-transfected cells were more prone to cell death. In the
treatment with 2 µg/mL VCR, the survival rate of miR
transfected cells was approximately half that of control cells. A
further increase of VCR concentration to 10 µg/mL led to a
60% and 75% reduction of survival rate in both miR-transfected
cells compared with non-transfected cells, suggesting that the
two miRs can potentially improve the efficiency of
chemotherapy.
To further confirm that the changes in expression of miR-381
and miR-495 were associated with changes in expression of
the MDR1 gene and the development of multi-drug resistance,
we constructed a pEGFP-MDR1 3’UTR vector containing the
3’-untranslated region (UTR) segment of MDR1. By transiently
introducing miR-381 or miR-495 mimics together with the
pEGFP-MDR1 3’UTR and an internal control (pDsRed2-N1) for
normalizing transfection efficiency into HCA2-hTERT, a human
foreskin fibroblast cell line, we found that GFP expression
decreased by approximately 20% in the presence of miR-381
or miR-495 (Figure 4E), proving that the two miRs can
modulate expression of the MDR1 gene by targeting its 3'-UTR.
UTR reporter assays with other miRs, miR-376a and
miR-369-3p, that have strongly reduced expression in
K562/AMD cells but are not predicted to target the MDR1 gene
were also performed. No obvious change in GFP expression
was observed (Figure S2), further confirming that the
expression of miR-381 and miR-495 is negatively correlated
with MDR1 expression and function.
A miR cluster on chromosome 14q32.31is down-
regulated in K562/ADM cells
Both miR-381 and miR-495 were found to be located within a
miR cluster spanning a distance of 20 kb in an imprinted region
at chromosome location 14q32.31 based on the UCSC human
genome assembly (GRCh37/hg19, February 2009, Figure 5A).
All miRs within the cluster were down-regulated in K562/ADM
cells according to our miRNAome profiling (Figure 5A and
Table 2). Importantly, reduced expression of a number of other
miRs in this region (including miR-494, miR-376c and miR-655
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Figure 4.  Functional analysis of miR-381 and miR-495 in K562/ADM cells.  (A) After transfection of K562/ADM cells with
mimics of miR-381, miR-495 or negative controls, or transfection with inhibitors in addition to mimics, MDR1 mRNA expression was
determined by real-time PCR. Expression values were normalized to GAPDH and are shown as the mean ± SD of three
independent experiments. * indicates a significant difference between the two groups of samples with p<0.05 calculated using a
two-sample t-test. (B) FACS analysis showed the different levels of P-gp expression in K562 cells and K562/ADM cells without
transfection, or transfected with scrambled sequences as negative controls or mimics alone or mimics plus inhibitors of miR-381 or
miR-495. (C) Microscopy images of Rh123 accumulation in K562 and K562/ADM cells with different treatments. Each sample had a
cell density of approximately 1×106 cells/mL. (D) Cell survival rate after transfection with mimics of miRs in the presence of 0, 2 or
10 µg/mL VCR. Data is shown as the mean ± SD of three independent experiments. (E) Relative GFP fluorescence intensity
compared to internal control DsRed was analyzed by FACS after co-transfection with mimics of miR-381 or miR-495 or negative
control. * indicates a significant difference between the two groups of samples with p<0.05 calculated using a two-sample t-test.
doi: 10.1371/journal.pone.0082062.g004
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in addition to miR-381 and miR-495) was confirmed in
K562/ADM cells by stem-loop real-time PCR analysis (Figures
3C and 5B).
Interestingly, approximately 13 ESTs were identified, from
the UCSC hg19 human genome assembly, in the surrounding
region of the miR-495/miR-381 cluster. Some miRs overlap
with the ESTs; for example, miR-495 matches part of the
sequence of EST AA613245 and miR-655 maps to EST
BG000132 (Figure 5A). To measure the expression of the
primary transcripts for miR-381 and miR-495, primer sets
designated A to E were designed based on the known
sequences of the ESTs (Figure 5A and Table S6). Reverse
transcriptase PCR products on 2% agarose gels showed
decreased EST expression in K562/ADM cells. However,
analysis of genomic DNA with the same primer sets showed
that this genomic region was not deleted in the K562/ADM cells
(Figure 5C), indicating that the loss of expression occurred at
the level of expression of the primary transcripts across this
genomic region. The real-time PCR results presented in Figure
5D show the expression levels of these ESTs in K562 and
K562/ADM cells with Ct values normalized to GAPDH. All the
ESTs displayed a clear reduction in expression in the MDR
cells with fold changes of 141, 82, 42, 36 and 31-times for A, B,
C, D and E respectively.
As can be seen in Figure 5D, all these ESTs had relatively
large fold decreases in MDR cells. The results also suggest
that ESTs A and B may be transcribed from the same primary
transcript that is different from that for EST C, while ESTs D
and E might be transcribed from yet another primary transcript.
This hypothesis is consistent with the transcription start sites
sourced from FANTOM cap analysis gene expression (CAGE)
tags [25] depicted in Figure 5D. ESTs A and B may share a
common TSS starting at chr14:101486788 and encode the
primary transcript for miR-494 and miR-495; EST C and
miR-376c may share the same TSS (chr14:101504476) while
ESTs D and E together with miR-381 and miR-655 may be
transcribed from chr14:101508809. Therefore, we conclude
that miR-381 and miR-495 may be the products of two different
primary transcripts.
Drosha, DGCR8 and Dicer are known to regulate the
processing of primary transcripts encoding miRs into mature
miRs in a stepwise manner. Thus, examining the expression of
Drosha, DGCR8 and Dicer in K562 and K562/ADM cells was
an essential step to determine whether the down-regulation of
miR-381 and miR-495 was related to dysregulation of these
endonucleases. Real-time PCR with primers designed to
uniquely target Drosha, DGCR8 and Dicer was conducted to
determine their mRNA expression (Figure 5E). There is no
evidence of differential expression of these endonucleases
between K562 and K562/ADM cells, which suggests that down-
regulation of miR-381 and miR-495 was not related to changes
in the miR processing system. Since both the mature and the
pre-miRs are down-regulated but their processing system
appears to be normally expressed, it is possible that these
results derive from decreased expression of the primary
transcripts encoding these miRs in MDR cells.
Discussion
A number of studies have revealed that miRs play critical
roles in the acquisition of MDR by cancer cells [14,15,26]. In
our study, we obtained a genome-wide profile of drug-induced
miRs in human leukemia K562 cells using next-generation
sequencing and identified and validated two miRs, miR-381
and miR-495, that may play a role in regulating the MDR1 gene
in leukemia cells. These two miRs were strongly down-
regulated in two MDR K562 cell lines derived by treatment with
ADM and VBL respectively, which suggests the possibility of
diagnostic or prognostic applications as well as constituting
potentially novel targets for therapy. MDR1/P-gp expression
can be altered, either directly or indirectly, by modulating the
levels of miR-381 or miR-495 in K562/ADM cells, hence
affecting the substrate efflux function of P-gp, demonstrating
the capacity of miR treatment to increase drug uptake in MDR
leukemia cells.
Although our knowledge of the biology of miRs has
advanced rapidly in recent years, much of the focus has been
on their processing, targeting and regulatory mechanisms.
Less is known about miR precursors, especially their primary
transcripts. In this study, we have shown that both the mature
forms and precursors of miR-381 and miR-495 are down-
regulated in K562/ADM cells (Figure 3C). Because of the
decreased expression of nearby ESTs (Figure 5), we draw the
conclusion that the dysregulation of mature miRs appears to
occur at the level of the primary transcripts as suggested by
previous research [27–30]. Furthermore, the different
expression patterns of the ESTs examined here and the CAGE
TSSs sourced from FANTOM [25] suggest that miR-381 and
miR-495 originate from different primary transcripts both of
which are decreased in expression.
MiR-381 and miR-495 are both located in a cluster of miRs
grouped within a 20 kb genomic region located at chromosome
region 14q32.31. There is limited information available on miR
clusters in general, although between 30-50% of miR genes
are found to occur in clusters in zebrafish, mouse and human
[31–33]. Clustered miRs are predicted to be transcribed as
polycistrons and to have similar expression patterns [34,35]. A
large cluster containing 40 miRs is located in the ~1 Mb
imprinted 14q32 domain in humans as predicted by Seitz et al.
[38] and the candidate miR cluster down-regulated in
K562/ADM cells in this study falls into this region. Thus our
data indicate that these miRs may be regulated by a common
mechanism and warrants further investigation.
Many miR genes are located in genomic regions that are
involved in chromosomal deletions or amplifications in human
cancers [36,37]. We found that expression of ESTs and miRs
in chromosomal region 14q32.31 is down-regulated in
K562/ADM cells, suggesting the existence of a chromosomal
deletion, insertion or translocation resulting from anticancer
drug treatment. However, PCR using genomic DNA indicated
that this region was intact in K562/ADM cells, excluding the
possibility of a large chromosomal deletion. It has been
reported that chromosome 14q32 is an unstable locus, with
frequent translocations in cancer. For example, a t(14,18) (q32;
q21) chromosomal translocation has been characterized in
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Figure 5.  Expression of primary transcripts in the miR cluster on chromosome 14q32.31.  (A) Schematic representation of
known EST sites and selected miRs shown in UCSC genome browser (Human Feb. 2009 (GRCh37/hg19)) at chromosome region
14q32.31. EST primer sets A to E are indicated in triangles below each EST. Transcription start sites sourced from FANTOM CAGE
tags are shown as arrows on the top of the 14q32.31 region. (B) Expression of selected miRs (miR-494, miR-495, miR-376c,
miR-381 and miR-655) in K562 and K562/ADM cells was validated by stem-loop real-time PCR. The Ct values of these miRs were
normalized to that of miR-425 whose level of expression was similar in the two cell lines. The relative expression of miR-494,
miR-495, miR-376c, miR-381, miR-655 and miR-16 in K562/ADM cells was calculated. The results are shown as the mean ± SD of
three independent experiments. (C) PCR products were resolved on a 2% agarose gel. (D) Expression of the primary transcripts in
both K562 and K562/ADM was determined by RT-PCR using primers designed against ESTs A to E. The data were normalized to
GAPDH. The results are shown as the mean ± SD of three independent experiments. Quantification of the change of expression
level in K562/ADM cells relative to K562 cells is shown on the bottom. (E) Expression of three human RNA nuclease genes, Drosha,
DGCR8 and Dicer, in both K562 and K562/ADM cells, was determined by real-time PCR. The expression values were normalized to
GAPDH, and are shown as the mean ± SD of three independent experiments.
doi: 10.1371/journal.pone.0082062.g005
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over 60% of human follicular lymphomas [38]; 28% of adult T-
cell leukemia/lymphomas display a chromosome 14q32
translocation [39] while 20% of childhood T-cell acute
lymphoblastic leukemias have a t(5;14) (q35; q32)
chromosomal translocation [40]. Hence, we speculate that a
translocation might be the cause of the dysregulated miR
cluster in MDR leukemia cells although we do not have direct
evidence of this and the details of a possible deletion, insertion
or translocation in this region of chromosome 14 have yet to be
investigated. It is thought that chromosomal instability is also
related to the DNA methylation and histone modification that
plays a critical role in epigenetic silencing of genes [41].
Therefore, we propose the alternative hypothesis that this
region could be subject to epigenetic regulation in MDR
leukemia cells leading to repression of miR expression.
Another point worth noting is that miR-381, miR-495 and
their clusters are located 40 kb downstream of clusters of small
nucleolar RNA (snoRNAs). This is another class of small non-
coding RNA molecules that primarily guide chemical
modifications of other RNAs [42]. In the human genome, at
least two snoRNA clusters belonging to the C/D box class of
snoRNAs are found in tandem repeats within the imprinted loci
at chromosome 14q32 and chromosome 15q11q13 [43,44].
Chromosome 14q32 contains 9 copies of SNORD113 and 31
copies of SNORD114 within the introns of a tissue-specific
non-coding human MEG8 RNA transcript. The functional roles
of these snoRNAs have yet to be investigated, although it has
been suggested that they play a role in the evolution and/or the
mechanism of epigenetic imprinting [43]. Interestingly, these
snoRNA and the miR clusters mapped to the human genome in
the same orientation. Furthermore, 23 out of a total of 41
snoRNAs located down-stream of SNORD113 and SNORD114
at chromosome region 14q32 were found to be significantly
down-regulated in K562/ADM cells (data not shown), in
agreement with the pattern of down-regulation of the miR
cluster. Whether down-regulation of the snoRNA and miR
clusters in K562/ADM cells is driven by a common mechanism
remains to be determined.
As a therapeutic strategy to overcome MDR, the use of
miR-381 and miR-495 may have some advantages over
conventional chemical inhibitors because they are native
molecules in normal human cells. Also, they are small
hydrophilic molecules, and thus able to modulate the
expression of P-gp in aqueous environments in contrast to
chemical inhibitors that are usually hydrophobic and function in
the lipid phase[45]. Another possible advantage of a miR-
based therapy would be the ability of a single miR to influence
multiple cellular pathways by targeting the 3’UTRs of hundreds
of different mRNAs [46,47]. However, the ability to affect a
broad range of targets might also be a double-edged sword
since any biological pathways regulated by these target genes
would be affected, if and when the expression of miR-381 or
miR-495 is changed, and might cause unwanted side effects.
Therefore we employed RT-PCR to examine changes in gene
expression as a result of down-regulation of miR-381 or
miR-495. Several genes including ZEB1, TET1, ARID4B,
MECOM, ZFPM2, that have putative miR binding sites and that
may be targets of both miR-381 and miR-495 were selected
based on the microRNA.org database. We found no obvious
changes in the expression of these genes after transfection
compared with the MDR1 gene which, as expected, showed
significantly decreased expression (Figure S3, note: log scale
on y-axis). A possible explanation could be that miR-381 and
miR-495 primarily target the MDR1 gene with the other genes
listed above being minor targets. However, we have only tested
the expression of a limited set of genes in this study and it is
possible that we have gained an incomplete view of the effects
of modulating intracellular miR-381 or miR-495 levels on the
expression of a broader range of genes. It would be interesting
to widen the scope and search for other affected genes in a
future study.
In conclusion, miR-381 and miR-495 are located within a
cluster of dozens of down-regulated miRs on chromosome
14q32.21 and may be functionally important in the
development of MDR in K562/ADM and K562/VBL cells. The
naturally unstable nature of the chromosome 14q32 region may
contribute to dysregulation of the primary transcripts of
miR-381 and miR-495, and thus lead to decreased expression
of the mature miR-381, miR-495 and the surrounding cluster of
miRs. Therapeutic intervention with either miR-381 or miR-495
targeting P-gp expression may be possible, but more evidence
would be needed to support this proposal. Use of a miR-based
therapy, in addition to conventional chemotherapeutic agents,
could potentially provide a next-generation approach to
treatment, and provide many benefits for cancer patients,
particularly for those with leukemia.
Supporting Information
Figure S1.  Phenotypes of parental and MDR K562 cells.
(A) Morphological changes after treatment of K562 cells with
ADM or VBL. (B) mRNA expression of MDR1 in both K562 and
K562/VBL cells was determined by real time PCR. Expression
values were normalized to GAPDH, and are shown as the
mean ± SD of three independent experiments. (C) P-gp
expression in both K562 and K562/VBL cells was determined
by FACS analysis and is shown in the histogram.
(TIF)
Figure S2.  MDR1 3’-UTR target assay for miR-369-3p and
miR-376a. Relative GFP fluorescence intensity compared to
internal control (DsRed) was analyzed by FACS after co-
transfection with mimics of miR-369-3p, miR-376a or negative
control. Both miR-369-3p and miR-376a show strongly reduced
expression in K562/ADM cells and are not predicted to target
the MDR1 gene.
(TIF)
Figure S3.  Expression of genes targeted by miR-381
and/or miR-495. Expression of representative genes targeted
by both miR-381 and miR-495 in K562 cells and K562/ADM
cells with or without transfection with miR mimics was
determined by real time-PCR. Expression values were
normalized to GAPDH, and are shown as the mean ± SD of
three independent experiments.
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(TIF)
Table S1.  Primers to validate gene expression by real time
PCR.
(DOC)
Table S2.  Primers to validate mature miRs by stem-loop
real-time PCR.
(DOC)
Table S3.  Sequences of miR mimics.
(DOC)
Table S4.  Sequences of miR inhibitors.
(DOC)
Table S5.  Up-regulated miRs with >10-fold increase in
expression in K562/ADM cells.
(DOC)
Table S6.  Primers to validate EST expression by real time
PCR.
(DOC)
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